ArticleEuropean journal of pediatrics2026
Feasibility and clinical outcomes of short-course intravenous antibiotic therapy in neonates under 28 days with urinary tract infection.
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evidence guiding the optimal duration of intravenous (IV) antibiotic therapy for urinary tract infections (UTI) in neonates under 28 days remains scarce. This study aimed to evaluate the feasibility and safety of a short IV antibiotic course (≤4 days) followed by oral treatment in neonates with UTI. We conducted a retrospective single-center study including neonates <28 days hospitalized for culture-proven UTI (≥10,000 leukocytes/mL and ≥10,000 CFU/mL of a single pathogen). Demographic, clinical, laboratory, imaging, and treatment data were collected. Outpatients and newborns with a postmenstrual age >35+6 weeks were included. Patients were stratified as low-risk (no severity criteria) or high-risk (clinical severity, bacteremia, pyelo-ureteral dilatation, or ESBL infection). The primary endpoint was 30-day recurrence after IV therapy. A total of 138 patients were included; (82% male, median age 15.5 days). 97 patients (71%) were classified as low-risk, and 95 of them (98%) received a short IV antibiotics course (≤4 days). Only one early recurrence occurred related to poor oral intake of antibiotic treatment during viral co-infection. Escherichia coli was the predominant pathogen (88%, 121/138). ESBL were identified in 3.6% (5/138) of neonates. Fifty-one patients (37%) were younger than 14 days, they presented less frequently with fever but received similar short IV courses without increased recurrence.
conclusionShort-course IV antibiotic therapy followed by oral treatment appears feasible and associated with favorable clinical outcomes for carefully selected neonates under 28 days with UTI and low risk factors for severe infection. These findings support a more individualized approach to antibiotic duration in this specific population and warrant prospective multicenter validation. WHAT IS KNOWN: • Evidence supports short IV antibiotic courses in infants >28 days with UTI. • Robust recommendations are lacking for neonates <28 days. WHAT IS NEW: • In clinically stable neonates <28 days without bacteremia, short IV therapy was not associated with increased recurrence. • Even neonates <14 days can be safely managed with this approach.
Indexed as
Identifiers
42848061What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.